Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Joller

Showing results (1-10 of 50) with videos related to

Pageof 5
Sort By:
Schweizerische Medizinische Wochenschrift|May 8, 1982
[Relevant immunological profiles]H Joller
International Archives of Allergy and Applied Immunology|January 1, 1984
IgG subclasses of anti-HBs antibodies in vaccinated and nonvaccinated individuals and in anti-HBs immunoglobulin preparationsF Skvaril, H Joller-Jemelka
Schweizerische Medizinische Wochenschrift|August 29, 1987
[HIV serology in the early stage of an HIV infection]H Joller-Jemelka, P J Grob
Schweizerische Medizinische Wochenschrift|January 2, 1982
[IgG-IgM cryoglobulinemia with a purpura-arthralgia-nephritis syndrome]A Fontana, B Doll, H Joller
Cancer|February 1, 1993
CA 242 is a new tumor marker for pancreatic cancerM A Röthlin, H Joller, F Largiadèr
Schweizerische Medizinische Wochenschrift|June 18, 1988
[The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma]M Röthlin, U Metzger, H Joller, et al.
Allergy|April 9, 1999
Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitisM K Kägi, H Joller-Jemelka, B Wüthrich
Allergy|January 1, 1995
Levels of soluble ICAM-1 in atopic dermatitis. A new marker for monitoring the clinical activity?B Wüthrich, H Joller-Jemelka, M K Kägi
Dermatology (Basel, Switzerland)|January 1, 1992
Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitisM K Kägi, H Joller-Jemelka, B Wüthrich
Schweizerische Medizinische Wochenschrift|April 1, 1978
[Serum immunoglobulins during immunosuppressive therapy following kidney transplantation]H Oehninger, H Joller, F Largiadèr, et al.
Pageof 5

Showing results (1-10 of 50) with videos related to

Sort By:
Pageof 5
Schweizerische Medizinische Wochenschrift|May 8, 1982
[Relevant immunological profiles]H Joller
International Archives of Allergy and Applied Immunology|January 1, 1984
IgG subclasses of anti-HBs antibodies in vaccinated and nonvaccinated individuals and in anti-HBs immunoglobulin preparationsF Skvaril, H Joller-Jemelka
Schweizerische Medizinische Wochenschrift|August 29, 1987
[HIV serology in the early stage of an HIV infection]H Joller-Jemelka, P J Grob
Schweizerische Medizinische Wochenschrift|January 2, 1982
[IgG-IgM cryoglobulinemia with a purpura-arthralgia-nephritis syndrome]A Fontana, B Doll, H Joller
Cancer|February 1, 1993
CA 242 is a new tumor marker for pancreatic cancerM A Röthlin, H Joller, F Largiadèr
Schweizerische Medizinische Wochenschrift|June 18, 1988
[The tumor markers CA 19.9, Ca 50 and CEA in the differential diagnosis of pancreatic carcinoma]M Röthlin, U Metzger, H Joller, et al.
Allergy|April 9, 1999
Soluble E-selectin correlates with disease activity in cyclosporin A-treated patients with atopic dermatitisM K Kägi, H Joller-Jemelka, B Wüthrich
Allergy|January 1, 1995
Levels of soluble ICAM-1 in atopic dermatitis. A new marker for monitoring the clinical activity?B Wüthrich, H Joller-Jemelka, M K Kägi
Dermatology (Basel, Switzerland)|January 1, 1992
Correlation of eosinophils, eosinophil cationic protein and soluble interleukin-2 receptor with the clinical activity of atopic dermatitisM K Kägi, H Joller-Jemelka, B Wüthrich
Schweizerische Medizinische Wochenschrift|April 1, 1978
[Serum immunoglobulins during immunosuppressive therapy following kidney transplantation]H Oehninger, H Joller, F Largiadèr, et al.
Pageof 5